A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers (HERIZON-BTC-01)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04466891 |
|
Recruitment Status :
Active, not recruiting
First Posted : July 10, 2020
Last Update Posted : March 31, 2023
|
Sponsor:
Zymeworks Inc.
Collaborator:
BeiGene, Ltd.
Information provided by (Responsible Party):
Zymeworks Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Active, not recruiting |
|---|---|
| Actual Primary Completion Date : | October 10, 2022 |
| Estimated Study Completion Date : | June 2024 |